AngioDynamics
This article was originally published in The Gray Sheet
Executive Summary
Company exits cardiovascular market Aug. 1 via sale of its AngioDynamics Ltd. interventional cardiology business to management, supported by the venture capital firms Alliance Investment Capital and ICC. The deal includes the division's Enniscorthy, Ireland manufacturing facility for electromechanical injectors and sterile, disposable devices. The move is in line with the parent firm's strategy to focus entirely on the interventional radiology market
You may also be interested in...
Maxwellia Delivers Two UK Menstrual Health Rx-To-OTC Switches
UK switch specialist Maxwellia delivers two “me too” reclassifications in the area of women's health: Evana Heavy Period Relief and Ultravana Period Pain Relief.
WHO Examines Ethical Criteria For Human Challenge Trials Ahead Of Next Health Emergency
The World Health Organization is looking to finalize its guidance on the ethical criteria that should be applied to studies that involve deliberately infecting healthy individuals to speed up research.
Irish Body Sets Out Five-Year Vision Strategy For Off-Patent Sector
With a focus on drug accessibility, supply chain resilience, and a balanced approach to sustainability, Medicines for Ireland “calls to action” with its five-year plan.